Compare · IPEX vs NVS
IPEX vs NVS
Side-by-side comparison of Inflection Point Acquisition Corp. V (IPEX) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IPEX and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS carries a market cap of $286.95B.
- IPEX has hit the wire 4 times in the past 4 weeks while NVS has been quiet.
- NVS has more recent analyst coverage (25 ratings vs 0 for IPEX).
- Company
- Inflection Point Acquisition Corp. V
- Novartis AG
- Price
- -
- -
- Market cap
- -
- $286.95B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 4
- 0
- Recent ratings
- 0
- 25
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest IPEX
- SEC Form 15-12G filed by Inflection Point Acquisition Corp. V
- Inflection Point Acquisition Corp. V filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 25-NSE filed by Inflection Point Acquisition Corp. V
- GOWell Technology Limited and Inflection Point Acquisition Corp. V Announce Closing of Business Combination
- Amendment: SEC Form SCHEDULE 13G/A filed by Inflection Point Acquisition Corp. V
- SEC Form 425 filed by Inflection Point Acquisition Corp. V
- Inflection Point Acquisition Corp. V filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 425 filed by Inflection Point Acquisition Corp. V
- SEC Form DEFA14A filed by Inflection Point Acquisition Corp. V
- Inflection Point Acquisition Corp. V filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Latest NVS
- Big Pharma Setbacks Create a New Wave of Rebound Plays
- Novartis AG upgraded by HSBC Securities
- Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
- RBC Capital Mkts initiated coverage on Novartis AG
- Novartis AG downgraded by Deutsche Bank
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- The Quest to Repair What Multiple Sclerosis Takes Away